OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Berchuck on Detecting PSMA Expression With a Novel Epigenomic Liquid Biopsy in mCRPC

September 24th 2024

Jacob E. Berchuck, MD, discusses the use of a novel epigenomic liquid biopsy platform to noninvasively detect PSMA expression in mCRPC.

Dr Kaklamani on the Role of Adjuvant Ribociclib in Early-Stage HR+/HER2– Breast Cancer

September 24th 2024

Virginia Kaklamani, MD, discusses the optimal role for adjuvant ribociclib alongside endocrine therapy in early-stage HR+/HER2– breast cancer.

Dr Banerjee on Deciding Between CAR T-Cell Therapy and Bispecific Antibodies in Myeloma

September 24th 2024

Rahul Banerjee, MD, FACP, discusses criteria utilized in deciding between treatment with bispecific antibodies and CAR T-cell therapy in multiple myeloma.

Dr Drakaki on a Case Study in ALK+ Refractory Metastatic RCC

September 24th 2024

Alexandra Drakaki, MD, PhD, discusses a case study of a patient with refractory metastatic renal cell carcinoma harboring an ALK rearrangement.

Dr Amanam on Criteria for Selecting a JAK Inhibitor in Myelofibrosis

September 23rd 2024

Idoroenyi Amanam, MD, discusses criteria for selecting patients with myelofibrosis who may benefit from JAK inhibitors.

Dr Singer on the Lack of Clinical Benefit for Immunotherapy Rechallenge in Advanced RCC

September 23rd 2024

Adam Singer, MD, PhD, discusses the lack of clinical benefit for sequential immunotherapy in advanced renal cell carcinoma.

Dr Chambers on Access, Toxicities, and Long-term Considerations for PARP Inhibitors in Ovarian Cancer

September 23rd 2024

Laura J. Chambers, DO, discusses challenges patients with ovarian cancer face in accessing PARP inhibitor treatment.

Dr Tang on the Current Role for Radiation Therapy in Advanced RCC

September 23rd 2024

Chad Tang, MD, discusses the potential role for radiation therapy in advanced renal cell carcinoma.

Dr Lim on the Significance of the FDA Approval of Adjuvant Ribociclib in HR+/HER2– Breast Cancer

September 23rd 2024

Bora Lim, MD, discusses the FDA approval of adjuvant ribociclib plus an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer.

Dr Ye on Early Efficacy Data for BL-B01D1 in Metastatic Urothelial Carcinoma

September 20th 2024

Dingwei Ye, MD, PhD, discusses the initial efficacy and safety of BL-B01D1 in locally advanced or metastatic urothelial carcinoma.

Dr El-Jawahri on the Benefits of Earlier Palliative Care in Hematologic Malignancies

September 20th 2024

Areej El-Jawahri, MD, discusses the potential benefits of earlier palliative care for patients with hematologic malignancies.

Dr Srinivas on the Role of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

September 19th 2024

Sandy Srinivas, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.

Dr Rimm on the Limitations of HER2 IHC Assays in Breast Cancer

September 19th 2024

David Rimm, MD, PhD, discusses the limitations of current HER2 immunohistochemistry assays in breast cancer.

Dr Secord on the Safety of Mirvetuximab in Recurrent Platinum-Sensitive Ovarian Cancer

September 19th 2024

Angeles A. Secord, MD, MHSc, discusses safety findings from the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive ovarian cancer.

Dr Drakaki on Paradigm-Shifting Trials in Non–Clear Cell RCC

September 19th 2024

Alexandra Drakaki, MD, PhD, discusses key trials that have shaped the treatment paradigm in non–clear cell renal cell carcinoma.

Dr Amanam on the Optimal Use of JAK Inhibitors in the Current Myelofibrosis Treatment Paradigm

September 19th 2024

Idoroenyi Amanam, MD, discusses the myelofibrosis treatment paradigm, highlighting patients who may derive the most benefit for JAK inhibitor treatment.

Dr Lonial on the Impact of the CoMMpass Study on Personalized Medicine in Multiple Myeloma

September 18th 2024

Sagar Lonial, MD, FACP, discusses the broad impact of the CoMMpass study on understanding the molecular underpinnings of multiple myeloma.

Dr Gordon on Shifts in the R/R MCL Treatment Paradigm

September 18th 2024

Leo I. Gordon, MD, discusses the evolution of the treatment paradigm in relapsed/refractory mantle cell lymphoma.

Dr Wolf on Unmet Needs With Surgery in Mesothelioma Treatment

September 18th 2024

Andrea Wolf, MD, MPH, discusses challenges in conducting randomized controlled trials to assess the role of surgery in the treatment of mesothelioma.

Dr Morgans on Previously Reported Data From the ARAMIS Trial in nmCRPC

September 18th 2024

Alicia Morgans, MD, MPH, discusses prior data and follow-up analysis of the ARAMIS trial in nonmetastatic castration-resistant prostate cancer.